ArticlePediatric health, medicine and therapeutics2026
Efficacy of Adding Intravenous Methylprednisolone to Nebulized Budesonide in RSV Pneumonia: Modification by Bacterial Co-Infection - A Retrospective Cohort Study.
Article in Pediatric health, medicine and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy of intravenous methylprednisolone plus nebulized budesonide (IV+NEB CS) versus nebulized budesonide alone (NEB CS) in infants with RSV pneumonia, and to assess the influence of bacterial co-infection. Methods: This retrospective study included 303 patients (≤36 months) with RSV pneumonia. Patients were divided into IV+NEB CS (n=140) and NEB CS (n=163) groups, then stratified by bacterial co-infection and antibiotic use. Primary outcomes were time to cough/fever/wheezing relief, disappearance of pulmonary signs, hospital stay, and glucocorticoid-related adverse events. Results: (1) Wheezing relief was faster in the IV+NEB CS group [2.0 (1.5,4.0) vs 3.0 (2.0,4.0) days, P=0.010], but other outcomes did not differ. (2) Subgroup B (IV+NEB CS without bacterial infection) had the shortest median wheezing relief [2.0 (1.0,3.0) days], pulmonary sign resolution [4.0 (3.0,5.0) days], and hospital stay [4.0 (3.0,5.0) days]. (3) Antibiotic use was independently associated with shorter symptom relief and discharge (all P<0.001); after adjusting for antibiotics, the main effect of IV+NEB CS was no longer significant for most outcomes. (4) Antibiotics also reduced CRP levels (P=0.002). (5) Adverse event rates did not differ between groups. Conclusion: In non-severe RSV pneumonia, adding intravenous methylprednisolone to nebulized budesonide provides no consistent independent benefit after accounting for antibiotic use. The apparent faster recovery with combination therapy was largely explained by antibiotics. Routine intravenous corticosteroids are not recommended. When bacterial co-infection is suspected, antibiotics should be prioritized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.